Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance

Pediatric Diabetes

Volumn 9, Issue 6, 2008, Pages 567-576

  Burgert, Tania S ^a   Duran, Elvira J ^a   Goldberg gell, Rachel ^a   Dziura, James ^a   Yeckel, Catherine W ^a   Katz, Stuart ^a   Tamborlane, William V ^a   Caprio, Sonia ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Body fat distribution; Heart rate recovery; Metformin

Indexed keywords

METFORMIN; PLACEBO;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EXERCISE; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE; HEART RATE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LOOSE FECES; METABOLISM; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT;

ADOLESCENT; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; EXERCISE TEST; FEMALE; GLUCOSE TOLERANCE TEST; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; OBESITY; RISK FACTORS;

EID: 56649107790     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2008.00434.x     Document Type: Article

References (38)

1. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004: 350: 2362-2374.
2. Bonora E, Formentini G, Calcaterra F et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002: 25: 1135-1141.
3. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001: 107: E55.
4. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001: 50: 1457-1461.
5. Srinivasan S, Ambler GR, Baur LA et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006: 91: 2074-2080.
6. Pasquali R, Gambineri A, Biscotti D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000: 85: 2767-2774.
7. de Aguiar LG, Bahia LR, Villela N et al. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006: 29: 1083-1089.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998: 352: 854-865.
9. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J Intern Med 2005: 257: 100-109.
10. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999: 341: 1351-1357.
11. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000: 132: 552-555.
12. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR Jr, Liu K. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA 2003: 290: 3092-3100.
13. Lind L, Andren B. Heart rate recovery after exercise is related to the insulin resistance syndrome and heart rate variability in elderly men. Am Heart J 2002:144: 666-672.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004: 27 (Suppl. 1): S5-S10.
15. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000: 23: 1227-1231.
16. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002: 19: 527-534.
17. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999: 22: 1462-1470.
18. Yeckel CW, Weiss R, Dziura J et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004: 89: 1096-1101.
19. Burgert TS, Taksali SE, Dziura J et al. Alanine aminotransferase levels and fatty liver in childhood obesity: Associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 2006: 91: 4287-4294.
20. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002: 87: 5044-5051.
21. Master AM The Master two-step test. Am Heart J 1968: 75: 809-837.
22. Master AM, Adams CW. The exercise tolerance test. JAMA 1968: 204: 80-81.
23. Londeree B, Moeschberger M. Effect of age and other factors on maximal heart rate. Res Q Exerc Sport 1982: 53: 297-304.
24. Gordon -Larsen P, Nelson MC, Popkin BM. Longitudinal physical activity and sedentary behavior trends: Adolescence to adulthood. Am J Prev Med 2004: 27: 277-283.
25. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res 2006: 60: 759-763.
26. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998: 338: 867-872.
27. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001: 108: 1167-1174.
28. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome -a randomised, double-blind, placebo-controlled trial. BJOG 2006: 113: 817-824.
29. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000: 278: E941-E948.
30. Perini R, Orizio C, Comande A, Castellano M, Beschi M, Veicsteinas A. Plasma norepinephrine and heart rate dynamics during recovery from submaximal exercise in man. Eur J Appl Physiol Occup Physiol 1989: 58: 879-883.
31. Arai Y, Saul JP, Albrecht P et al. Modulation of cardiac autonomic activity during and immediately after exercise. Am J Physiol 1989: 256: H132-H141.
32. Emdin M, Gastaldelli A, Muscelli E et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss. Circulation 2001: 103: 513-519.
33. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: Effect of metformin administration. Am J Hypertens 2004: 17: 223-227.
34. Nathan DM, Davidson MB, De Fronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care 2007: 30: 753-759.
35. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005: 28: 902-909.
36. Weiss R, Taksali SE, Dufour S et al. The "Obese Insulin Sensitive"adolescent -importance of adiponectin and lipid partitioning. J Clin Endocrinol Metab 2005: 3731-3737.
37. Burgert TS, Dziura J, Yeckel C et al. Microalbuminuria in pediatric obesity: Prevalence and relation to other cardiovascular risk factors. Int J Obes (Lond) 2006:30: 273-280.
38. Freemark M. Pharmacotherapy of childhood obesity: An evidence-based, conceptual approach. Diabetes Care 2007:30: 395-402.